Jiangzhou Shi

Wuhan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Harnessing Vδ1+ T cells for next-generation immunotherapy: from mechanistic insights to clinical translation.

Harnessing Vδ1+ T cells for next-generation immunotherapy: from mechanistic insights to clinical translation.

Journal: Frontiers in immunology

Published: March 10, 2026

Upregulation of the TCA Cycle and Oxidative Phosphorylation Enhances the Fitness of CD99 CAR-T Cells Under Dynamic Cultivation.

Upregulation of the TCA Cycle and Oxidative Phosphorylation Enhances the Fitness of CD99 CAR-T Cells Under Dynamic Cultivation.

Journal: International journal of molecular sciences

Published: November 06, 2025

shRNA-based PD-1 suppression preserves memory phenotype and function of CD19-targeted CAR-T cell.

shRNA-based PD-1 suppression preserves memory phenotype and function of CD19-targeted CAR-T cell.

Journal: Translational cancer research

Published: May 04, 2025

Erratum: JUN mediates glucocorticoid resistance by stabilizing HIF1a in T cell acute lymphoblastic leukemia.

Erratum: JUN mediates glucocorticoid resistance by stabilizing HIF1a in T cell acute lymphoblastic leukemia.

Journal: iScience

Published: April 25, 2025

Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy.

Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: August 08, 2024

ETV7 limits the antiviral and antitumor efficacy of CD8+ T cells by diverting their fate toward exhaustion.

ETV7 limits the antiviral and antitumor efficacy of CD8+ T cells by diverting their fate toward exhaustion.

Journal: Nature cancer

Published: March 13, 2024

JUN mediates glucocorticoid resistance by stabilizing HIF1a in T cell acute lymphoblastic leukemia.

JUN mediates glucocorticoid resistance by stabilizing HIF1a in T cell acute lymphoblastic leukemia.

Journal: iScience

Published: September 05, 2023

Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8+ T cells in the tumor microenvironment.

Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8+ T cells in the tumor microenvironment.

Journal: Cell metabolism

Published: October 27, 2022

Establishment of a New Cryopreservation Solution for Chimeric Antigen Receptor T Cells.

Establishment of a New Cryopreservation Solution for Chimeric Antigen Receptor T Cells.

Journal: Biopreservation and biobanking

Published: March 16, 2022

The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.

The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.

Journal: Scientific reports

Published: November 15, 2021

CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.

CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.

Journal: Journal of hematology & oncology

Published: August 19, 2021

Showing 1-11 of 11

Last Updated: 09/26/2026